156 GSK Annual Report 2018 Notes to the financial statements continued 6.
Turnover and segment information continued Geographical information The UK is regarded as being the Groups country of domicile.
2018 2017 2016 Turnover by location of customer m m m UK 923 940 1,056 US 11,982 11,263 10,197 Rest of World 17,916 17,983 16,636 External turnover 30,821 30,186 27,889 2018 2017 Non-current assets by location of subsidiary m m UK 6,118 6,824 US 7,540 6,841 Rest of World 20,768 20,901 Non-current assets 34,426 34,566 Non-current assets by location excludes amounts relating to other investments, deferred tax assets, derivative financial instruments, pension assets, amounts receivable under insurance contracts and certain other non-current receivables.
Other operating income expense 2018 2017 2016 m m m Fair value remeasurements of equity investments under IFRS 9 16 Disposal of businesses and assets 258 195 283 Fair value remeasurements on contingent consideration recognised in business combinations 1,252 1,012 2,205 Remeasurement of ViiV Healthcare put option liabilities and preferential dividends 58 13 577 Remeasurement of Consumer Healthcare put option liability 658 1,186 1,133 Fair value adjustments on derivative financial instruments 3 9 3 Other expense income 7 9 23 Impairment of available-for-sale equity investments under IAS 39 30 47 Disposal of available-for-sale equity investments under IAS 39 37 254 1,588 1,965 3,405 Disposal of businesses and assets in 2018 included a profit of 119 million on the disposal of tapinarof to Dermavant Sciences, a profit of 33 million on the disposal of Consumer Healthcare tail brands in the US and a gain arising from the increase in value of the shares in Hindustan Unilever Limited to be received on the disposal of Horlicks and other Consumer Healthcare brands, which is expected to complete by the end of 2019, net of disposal costs.
Fair value remeasurements on contingent consideration recognised in business combinations included 1,188 million related to the acquisition of the former Shionogi-ViiV Healthcare joint venture and 56 million payable to Novartis related to the Vaccines acquisition and fair value movements on derivatives hedging foreign exchange exposure.
